Swedish Orphan Biovitrum (BIOVF) Expected to Announce Earnings on Tuesday

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) is expected to be releasing its resultson Tuesday, April 28th. Analysts expect Swedish Orphan Biovitrum to post earnings of $0.3724 per share and revenue of $746.6180 million for the quarter.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings results on Thursday, February 5th. The company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Swedish Orphan Biovitrum had a net margin of 1.43% and a return on equity of 15.74%. The company had revenue of $846.23 million for the quarter, compared to analysts’ expectations of $879.40 million.

Swedish Orphan Biovitrum Stock Performance

Shares of Swedish Orphan Biovitrum stock opened at $39.87 on Friday. Swedish Orphan Biovitrum has a fifty-two week low of $25.80 and a fifty-two week high of $42.22. The firm has a market cap of $14.19 billion, a PE ratio of 306.72 and a beta of 0.35. The business’s fifty day moving average is $39.73 and its two-hundred day moving average is $36.83. The company has a quick ratio of 0.59, a current ratio of 0.90 and a debt-to-equity ratio of 0.14.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Danske lowered Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, February 19th. BNP Paribas Exane raised Swedish Orphan Biovitrum to an “outperform” rating in a research note on Tuesday, February 10th. Finally, Barclays reissued an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy”.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm‐based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high‐value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in‐licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto‐inflammatory conditions.